Development of ionic liquid-coated PLGA nanoparticles for applications in intravenous drug delivery

Good's buffer based highly biocompatible ionic liquid modified PLGA nanoparticles for the selective uptake in cancer cells

“…Similarly, in Group 2, CTricine-NPs, CTES-NPs, and CTAPSO-NPs, which are greater compared to CACES-NPs, are likely due to more IL being present on each particle, evidenced by the corresponding amounts of these GBILs as 1.4-fold, 2.4-fold and 2-fold higher per NP of PLGA as compared to ACES (as determined by NMR measurements, Table S1, ESI†). 50 Contrarily, CTAPS has 2.3-fold more IL per NP but is smaller than CACES-NPs. The greater size of CTricine, CTES, and CTAPSO NPs, unlike ACES NPs, is suggested to be due to the absence of hydroxyl groups in CACES IL (Fig.…”

Ionic liquids revolutionizing biomedicine: recent advances and emerging opportunities

“…62 Furthermore, a library of choline carboxylate ILs assembled on polymeric nanoparticles was constructed to break biological barriers and prolong drug circulation for intravenous delivery. 290 These findings and protocols highlighted the potential of ILs for advanced nanoparticle modification toward the development of more effective and precisely targeted therapies.…”

Imidazolium-based zwitterionic liquid-modified PEG–PLGA nanoparticles as a potential intravenous drug delivery carrier

“…Qualitative flow cytometric and quantitative plate reader studies were performed using commercially purchased BALB/c blood following a previously published protocol. 5,45,83 Briefly, 1 mg mL −1 concentrated nanoparticles were combined with 500 μL of whole blood at a 1 : 10 ratio on ice, and samples were briefly mechanically mixed by inversion, followed by a 20 min incubation at 37 °C on a shaker (VMR orbital shaker) at 500 rpm. Subsequently, all samples were centrifuged at 1000g and 4 °C for 10 min to isolate the components in whole blood.…”